{"id":14385,"date":"2026-07-21T08:00:00","date_gmt":"2026-07-21T06:00:00","guid":{"rendered":"https:\/\/www.msd.ch\/de\/?post_type=news_item&#038;p=14385"},"modified":"2026-07-15T15:34:49","modified_gmt":"2026-07-15T13:34:49","slug":"swissmedic-erteilt-zulassung-fur-keytruda-in-kombination-mit-enfortumab-vedotin-fuer-muskelinvasives-blasenkarzinom","status":"publish","type":"news_item","link":"https:\/\/www.msd.ch\/de\/news\/swissmedic-erteilt-zulassung-fur-keytruda-in-kombination-mit-enfortumab-vedotin-fuer-muskelinvasives-blasenkarzinom\/","title":{"rendered":"Swissmedic erteilt Zulassung f\u00fcr KEYTRUDA\u00ae (Pembrolizumab) in Kombination mit Enfortumab vedotin (EV), als neoadjuvante Behandlung und anschliessend nach radikaler Zystektomie als adjuvante Behandlung von erwachsenen Patienten mit muskelinvasivem Blasenkarzinom (MIBC), f\u00fcr die eine cisplatinhaltige Chemotherapie nicht geeignet ist."},"content":{"rendered":"","protected":true},"excerpt":{"rendered":"","protected":true},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"footnotes":""},"tags":[30],"class_list":["post-14385","news_item","type-news_item","status-publish","post-password-required","hentry","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>KEYTRUDA\u00ae + Enfortumab vedotin: Zulassung bei MIBC<\/title>\n<meta name=\"description\" content=\"Swissmedic erteilt die Zulassung f\u00fcr KEYTRUDA\u00ae plus Enfortumab vedotin zur perioperativen Behandlung von erwachsenen Patienten mit MIBC.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.msd.ch\/de\/news\/swissmedic-erteilt-zulassung-fur-keytruda-in-kombination-mit-enfortumab-vedotin-fuer-muskelinvasives-blasenkarzinom\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"KEYTRUDA\u00ae + Enfortumab vedotin: Zulassung bei MIBC\" \/>\n<meta property=\"og:description\" content=\"Swissmedic erteilt die Zulassung f\u00fcr KEYTRUDA\u00ae plus Enfortumab vedotin zur perioperativen Behandlung von erwachsenen Patienten mit MIBC.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.msd.ch\/de\/news\/swissmedic-erteilt-zulassung-fur-keytruda-in-kombination-mit-enfortumab-vedotin-fuer-muskelinvasives-blasenkarzinom\/\" \/>\n<meta property=\"og:site_name\" content=\"msd.ch\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.msd.ch\\\/de\\\/news\\\/swissmedic-erteilt-zulassung-fur-keytruda-in-kombination-mit-enfortumab-vedotin-fuer-muskelinvasives-blasenkarzinom\\\/\",\"url\":\"https:\\\/\\\/www.msd.ch\\\/de\\\/news\\\/swissmedic-erteilt-zulassung-fur-keytruda-in-kombination-mit-enfortumab-vedotin-fuer-muskelinvasives-blasenkarzinom\\\/\",\"name\":\"KEYTRUDA\u00ae + Enfortumab vedotin: Zulassung bei MIBC\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.msd.ch\\\/de\\\/#website\"},\"datePublished\":\"2026-07-21T06:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.msd.ch\\\/de\\\/news\\\/swissmedic-erteilt-zulassung-fur-keytruda-in-kombination-mit-enfortumab-vedotin-fuer-muskelinvasives-blasenkarzinom\\\/#breadcrumb\"},\"inLanguage\":\"en-US\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.msd.ch\\\/de\\\/#website\",\"url\":\"https:\\\/\\\/www.msd.ch\\\/de\\\/\",\"name\":\"msd.ch\",\"description\":\"MSD erforscht und entwickelt Medikamente und Impfstoffe, die Leben retten und die Gesundheit von Patienten verbessern sollen. In der Schweiz setzen sich 1000 Mitarbeitende in Luzern und Z\u00fcrich daf\u00fcr ein.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.msd.ch\\\/de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"KEYTRUDA\u00ae + Enfortumab vedotin: Zulassung bei MIBC","description":"Swissmedic erteilt die Zulassung f\u00fcr KEYTRUDA\u00ae plus Enfortumab vedotin zur perioperativen Behandlung von erwachsenen Patienten mit MIBC.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.msd.ch\/de\/news\/swissmedic-erteilt-zulassung-fur-keytruda-in-kombination-mit-enfortumab-vedotin-fuer-muskelinvasives-blasenkarzinom\/","og_locale":"en_US","og_type":"article","og_title":"KEYTRUDA\u00ae + Enfortumab vedotin: Zulassung bei MIBC","og_description":"Swissmedic erteilt die Zulassung f\u00fcr KEYTRUDA\u00ae plus Enfortumab vedotin zur perioperativen Behandlung von erwachsenen Patienten mit MIBC.","og_url":"https:\/\/www.msd.ch\/de\/news\/swissmedic-erteilt-zulassung-fur-keytruda-in-kombination-mit-enfortumab-vedotin-fuer-muskelinvasives-blasenkarzinom\/","og_site_name":"msd.ch","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.msd.ch\/de\/news\/swissmedic-erteilt-zulassung-fur-keytruda-in-kombination-mit-enfortumab-vedotin-fuer-muskelinvasives-blasenkarzinom\/","url":"https:\/\/www.msd.ch\/de\/news\/swissmedic-erteilt-zulassung-fur-keytruda-in-kombination-mit-enfortumab-vedotin-fuer-muskelinvasives-blasenkarzinom\/","name":"KEYTRUDA\u00ae + Enfortumab vedotin: Zulassung bei MIBC","isPartOf":{"@id":"https:\/\/www.msd.ch\/de\/#website"},"datePublished":"2026-07-21T06:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.msd.ch\/de\/news\/swissmedic-erteilt-zulassung-fur-keytruda-in-kombination-mit-enfortumab-vedotin-fuer-muskelinvasives-blasenkarzinom\/#breadcrumb"},"inLanguage":"en-US"},{"@type":"WebSite","@id":"https:\/\/www.msd.ch\/de\/#website","url":"https:\/\/www.msd.ch\/de\/","name":"msd.ch","description":"MSD erforscht und entwickelt Medikamente und Impfstoffe, die Leben retten und die Gesundheit von Patienten verbessern sollen. In der Schweiz setzen sich 1000 Mitarbeitende in Luzern und Z\u00fcrich daf\u00fcr ein.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.msd.ch\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/news_item\/14385","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":9,"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/news_item\/14385\/revisions"}],"predecessor-version":[{"id":14395,"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/news_item\/14385\/revisions\/14395"}],"wp:attachment":[{"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/media?parent=14385"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/tags?post=14385"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}